The researchers behind a systematic review of existing clinical trials concluded that the use of drugs in the GLP-1 RA class, like Ozempic, was associated with an increased risk of gallbladder diseases, according to a 2022 article published in the journal JAMA Internal Medicine
Perlman told me
Some patients need slightly higher doses, while others benefit from nutritional adjustments
The effects were more pronounced in patients with higher BMI, and attenuated in those with lower BMI. The associations observed in the main analysis were similar in sensitivity analyses restricting urgent HF visits in the FLOW trial to adults requiring IV therapy and when investigator-reported events of hospitalization and urgent visits due to HF were used instead of adjudicated events
(2) limited central nervous system penetration resulting in insufficient pharmacodynamic target engagement at the doses studied
54, Suite 105, Lutz, FL 33549 | 813-859-6604